In a big relief for parents, the Subject Expert Committee on Covid-19 has granted emergency use approval to Bharat Biotech's Covaxin for children in the 2-18 years age group.
The advisory committee “National Technical Advisory Group on Immunisation” (NTAGI), recommended that those people who have recovered from Covid-19 should take vaccine after 6 months.
The gap between two doses of Covishield vaccine should be increased to 12-16 weeks, a Central Government panel has recommended on Thursday.
Hyderabad-based Bharat Biotech has been granted permission to conduct the phase 2 and phase 3 clinical trials of its COVID-19 vaccine ‘Covaxin’ on children between the 2 to age 18.
Pfizer has claimed efficacy against the new mutation found in the UK strain.
The Union Health Minister Dr Harsh Vardhan on Saturday informed that Covid vaccine will be free across the country. COVID-19 vaccinations
Covishield, developed by the University of Oxford and drug manufacturer AstraZeneca, has become the first Coivd-19 vaccine to get conditional approval for emergency use in India.
Applications for the emergency use of Covid-19 vaccine by Serum Institute of India (SII) and Bharat Biotech are not rejected.